With the FDA in turmoil, the ‘revolving door’ with industry is spinning faster

What's new in pharma

April 25, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | With the FDA in turmoil, the 'revolving door' with industry is spinning faster The departures appear to run counter to health secretary Robert F. Kennedy Jr.'s goal of eliminating conflicts of interest. By Allison DeAngelis, Jason Mast, and Elaine Chen STAT+ | Vanderbilt medical center warns suppliers not to raise prices due to tariffs, or they may not get paid Hospitals and health plans are concerned about price hikes, although VUMC is taking a particularly aggressive stance. By Ed Silverman STAT+ | Belgian antitrust regulator fines three companies $12.8 million over pharmacy displays The investigation is only the latest effort by a European country to scrutinize the pharmaceutical industry. By Ed Silverman Jose Luis Magana/AP STAT+ | Court ruling opens door to FDA action against Ozempic compounders The ruling is the latest development in the fight between compounding pharmacies and pharma companies over who can make GLP-1 drugs and when. By Elaine Chen STAT+ | Struggling lobbyists, panicked clients: D.C. comes to grips with Trump's second term Trump's second term is playing out a lot differently than health care companies and their lobbyists hoped for. By Daniel Payne

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser